

# Vivek Verma

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5202351/publications.pdf>

Version: 2024-02-01

97  
papers

2,110  
citations

361413

20  
h-index

330143

37  
g-index

98  
all docs

98  
docs citations

98  
times ranked

2866  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials. <i>Cancers</i> , 2022, 14, 1048.	3.7	5
2	Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. <i>Clinical Lung Cancer</i> , 2021, 22, e451-e465.	2.6	26
3	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Respiratory Medicine</i> , 2021, 9, 467-475.	10.7	277
4	Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial. <i>Clinical Lung Cancer</i> , 2021, 22, e211-e214.	2.6	6
5	Transparency in reporting of phase 3 cancer clinical trial results. <i>Acta Oncologica</i> , 2021, 60, 191-194.	1.8	3
6	The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. <i>Clinical Lung Cancer</i> , 2021, 22, e84-e97.	2.6	19
7	Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era?. <i>Translational Lung Cancer Research</i> , 2021, 10, 5-8.	2.8	1
8	A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa102.	2.9	81
9	Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. <i>Translational Oncology</i> , 2021, 14, 100983.	3.7	18
10	Management, outcomes, and prognostic factors of adult primary spinal cord gliomas. <i>Journal of Clinical Neuroscience</i> , 2021, 84, 8-14.	1.5	6
11	Outcomes following stereotactic radiosurgery or whole brain radiation therapy by molecular subtype of metastatic breast cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 341-351.	0.6	4
12	Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. <i>Journal of Clinical Neuroscience</i> , 2021, 85, 115-121.	1.5	9
13	Comparative Analysis of 5-Year Clinical Outcomes and Patterns of Failure of Proton Beam Therapy Versus Intensity Modulated Radiation therapy for Prostate Cancer in the Postoperative Setting. <i>Practical Radiation Oncology</i> , 2021, 11, e195-e202.	2.1	3
14	Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 812-819.	2.0	11
15	Cost-Effectiveness Models of Proton Therapy for Head and Neck: Evaluating Quality and Methods to Date. <i>International Journal of Particle Therapy</i> , 2021, 8, 339-353.	1.8	5
16	Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. <i>Seminars in Radiation Oncology</i> , 2021, 31, 217-226.	2.2	2
17	Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials. <i>International Journal of Cancer</i> , 2021, 149, 1683-1690.	5.1	2
18	Impact of radiation therapy facility volume on survival in patients with cancer. <i>Cancer</i> , 2021, 127, 4081-4090.	4.1	10

#	ARTICLE	IF	CITATIONS
19	Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51?. <i>Radiotherapy and Oncology</i> , 2021, 162, 52-59.	0.6	7
20	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 60-67.	0.6	45
21	Stereotactic radiotherapy for early-stage (T1-2N0) small cell lung cancer: Where are we now and where are we going?. <i>Lung Cancer</i> , 2021, 160, 187-189.	2.0	1
22	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. <i>Lancet Oncology</i> , The, 2021, 22, 1448-1457.	10.7	154
23	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	1.3	4
24	Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa103.	2.9	15
25	Phase I Trial of Dose-Escalated Five-Fraction Stereotactic Ablative Radiotherapy for Early-Stage Lung Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e451.	0.8	0
26	SABR for operable stage I non-small-cell lung cancer: comparison to surgery – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e537-e538.	10.7	0
27	Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 32, 1125-1132.	0.6	4
28	Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer. <i>Laryngoscope</i> , 2020, 130, E171-E176.	2.0	12
29	Clinical presentation, national practice patterns, and outcomes of breast adenomyoepithelioma. <i>Breast Journal</i> , 2020, 26, 653-660.	1.0	19
30	Factors predicting for patient refusal of head and neck cancer therapy. <i>Head and Neck</i> , 2020, 42, 33-42.	2.0	17
31	Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. <i>Practical Radiation Oncology</i> , 2020, 10, 324-329.	2.1	11
32	Exclusion of patients with brain metastases from cancer clinical trials. <i>Neuro-Oncology</i> , 2020, 22, 577-579.	1.2	18
33	Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. <i>Cancers</i> , 2020, 12, 2636.	3.7	4
34	Phase I/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1919-1927.	1.1	53
35	Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 673-682.	1.4	3
36	Professional Medical Writer Assistance in Oncology Clinical Trials. <i>Oncologist</i> , 2020, 25, e1812-e1815.	3.7	5

#	ARTICLE	IF	CITATIONS
37	Optimizing current standard of care therapy for stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2033-2039.	2.8	2
38	The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103006.	4.4	14
39	Prevalence and clinical characterization of cancer patients with asymptomatic SARS-CoV-2 infection history. <i>Journal of Infection</i> , 2020, 81, e22-e24.	3.3	11
40	The Diminishing Impact of Margin Definitions and Width on Local Recurrence Rates following Breast-Conserving Therapy for Early-Stage Invasive Cancer: A Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4628-4636.	1.5	9
41	Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review. <i>Practical Radiation Oncology</i> , 2020, 10, 423-433.	2.1	6
42	Evidence-based methodology for obtaining commercial insurance coverage of stereotactic radiosurgery for intractable epilepsy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 899-901.	0.6	1
43	Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 1225-1231.	1.2	0
44	Abscopal Response Rates after Salvage Radiation in Patients with Progressive Disease on Immunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e120-e121.	0.8	3
45	Repeat Stereotactic Ablative Radiotherapy for Isolated Local Recurrence of Early-Stage NSCLC. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e139-e140.	0.8	0
46	Low-Dose Radiation Decreases Cancer-Associated Fibroblasts and May Increase T-Cell Trafficking into Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e530-e531.	0.8	3
47	Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e550-e551.	0.8	1
48	181: Epidemiology of Synchronous Lung Metastases. <i>Radiotherapy and Oncology</i> , 2020, 150, S77-S78.	0.6	0
49	National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. <i>JAMA Network Open</i> , 2020, 3, e2013605.	5.9	47
50	Hippocampal-Sparing Radiotherapy for Patients With Glioblastoma and Grade II-III Gliomas. <i>JAMA Oncology</i> , 2020, 6, 981.	7.1	8
51	Management and outcomes of primary anorectal melanoma in the United States. <i>Future Oncology</i> , 2020, 16, 329-338.	2.4	13
52	Local management of preinvasive and clinical T1-3 penile cancer: utilization of diverse treatment modalities. <i>Future Oncology</i> , 2020, 16, 955-960.	2.4	5
53	Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 150, 114-120.	0.6	66
54	Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2020, 21, e583-e591.	2.6	11

#	ARTICLE	IF	CITATIONS
55	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. <i>JAMA Oncology</i> , 2020, 6, 1028.	7.1	122
56	Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinoma. <i>Hpb</i> , 2020, 22, 770-778.	0.3	11
57	De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials. <i>Oral Oncology</i> , 2020, 103, 104608.	1.5	37
58	Patterns of management and outcomes of unifocal versus multifocal glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 74, 155-159.	1.5	20
59	Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases. <i>Frontiers in Oncology</i> , 2020, 10, 517.	2.8	5
60	Radiotherapy workflow and protection procedures during the Coronavirus Disease 2019 (COVID-19) outbreak: Experience of the Hubei Cancer Hospital in Wuhan, China. <i>Radiotherapy and Oncology</i> , 2020, 148, 203-210.	0.6	80
61	Prognostic role of chemotherapy, radiotherapy dose, and extent of surgical resection in adult medulloblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 76, 154-160.	1.5	4
62	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1 Resistant Model of Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 883-894.	3.4	48
63	Performance Status Restriction in Phase III Cancer Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1322-1326.	4.9	18
64	Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2020, 12, 6476-6493.	1.4	0
65	Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1069-e1079.	1.9	8
66	Paravertebral Muscle Training in Patients with Unstable Spinal Metastases Receiving Palliative Radiotherapy: An Exploratory Randomized Feasibility Trial. <i>Cancers</i> , 2019, 11, 1771.	3.7	17
67	Stereotactic radiosurgery for brain metastases from newly diagnosed small cell lung cancer: practice patterns and outcomes. <i>Acta Oncologica</i> , 2019, 58, 491-498.	1.8	28
68	Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 134, 44-49.	0.6	12
69	Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes. <i>Lung Cancer</i> , 2019, 130, 93-100.	2.0	15
70	Postmastectomy radiation therapy for triple negative, node-negative breast cancer. <i>Radiotherapy and Oncology</i> , 2019, 132, 48-54.	0.6	17
71	Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. <i>Radiotherapy and Oncology</i> , 2019, 132, 55-62.	0.6	24
72	Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 76-83.	2.0	7

#	ARTICLE	IF	CITATIONS
73	Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 131, 145-149.	0.6	18
74	Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. <i>Radiotherapy and Oncology</i> , 2019, 132, 188-196.	0.6	20
75	National practice patterns of proton versus photon therapy in the treatment of adult patients with primary brain tumors in the United States. <i>Acta Oncologica</i> , 2019, 58, 66-73.	1.8	11
76	The impact of comorbidity on overall survival in elderly nasopharyngeal carcinoma patients: a National Cancer Data Base analysis. <i>Cancer Medicine</i> , 2018, 7, 1093-1101.	2.8	21
77	Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer. <i>Cancer Medicine</i> , 2018, 7, 1604-1611.	2.8	12
78	Treatment approaches for nasopharyngeal adenoid cystic carcinoma. <i>Acta Oncologica</i> , 2018, 57, 995-1001.	1.8	9
79	Human papillomavirus and nasopharyngeal cancer. <i>Head and Neck</i> , 2018, 40, 696-706.	2.0	31
80	Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis. <i>Lung Cancer</i> , 2018, 120, 7-13.	2.0	21
81	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. , 2018, 6, 128.		233
82	National Cancer Database report of nonmetastatic esophageal small cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 6365-6373.	2.8	6
83	Dosimetric Comparison of Proton Radiation Therapy, Volumetric Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy Based on Intracranial Tumor Location. <i>Cancers</i> , 2018, 10, 401.	3.7	41
84	Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e97.	2.2	6
85	Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival. <i>Clinical Lung Cancer</i> , 2018, 19, e901-e912.	2.6	46
86	Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States. <i>Clinical Lung Cancer</i> , 2018, 19, e685-e692.	2.6	18
87	Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 502-510.	2.6	2
88	Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial). <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 911-920.	2.0	23
89	Economic sustainability of immune-checkpoint inhibitors: the looming threat. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 721-722.	27.6	17
90	National Practice Patterns for Clinical T1N0 Nasopharyngeal Cancer in the Elderly: A National Cancer Data Base Analysis. <i>Anticancer Research</i> , 2018, 38, 1651-1657.	1.1	0

#	ARTICLE	IF	CITATIONS
91	Utilization of Neoadjuvant Intensity-modulated Radiation Therapy for Rectal Cancer in the United States. <i>Anticancer Research</i> , 2018, 38, 2923-2927.	1.1	3
92	Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. <i>Radiation Oncology</i> , 2017, 12, 71.	2.7	9
93	Classic Studies on the Potential of Stem Cell Neuroregeneration. <i>Journal of the History of the Neurosciences</i> , 2016, 25, 123-141.	0.9	3
94	Atypical teratoid rhabdoid tumor: long-term survival after chemoradiotherapy. <i>Child's Nervous System</i> , 2015, 31, 1393-1399.	1.1	9
95	Treatment Costs of Early-Stage Lung Cancers Detected by Low-Dose Computed Tomography Screening. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 207-208.	0.8	16
96	Nonalcoholic Wernicke's Encephalopathy Associated with Unintentional Weight Loss, Cholecystectomy, and Intractable Vomiting: The Role of Dual Thiamine and Corticosteroid Therapy. <i>Case Reports in Neurological Medicine</i> , 2014, 2014, 1-5.	0.4	2
97	Proton beam radiotherapy for esophageal cancer: challenges and opportunities in the modern era. <i>Precision Radiation Oncology</i> , 0, , .	1.1	0